CASI PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value
CASI PHARMACEUTICALS, INC. (CASIF) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value of $36.90 per share for the 12-month period ending 2023-12-31, per its 20-F filed 2025-03-31.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue · last filed 2025-03-31
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 12 month |
|---|---|
| 2023-12-31 | $36.90 20-F · filed 2025-03-31 |
| 2021-12-31 | $71.90 20-F · filed 2024-03-28 |
| 2020-12-31 | $37.50 20-F · filed 2023-04-26 |